427 related articles for article (PubMed ID: 30519894)
1. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
[TBL] [Abstract][Full Text] [Related]
2. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
Nassehi D
Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
4. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
5. Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas.
Oya S; Kawai K; Nakatomi H; Saito N
J Neurosurg; 2012 Jul; 117(1):121-8. PubMed ID: 22559847
[TBL] [Abstract][Full Text] [Related]
6. Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.
Bernatz S; Monden D; Gessler F; Radic T; Hattingen E; Senft C; Seifert V; Ronellenfitsch MW; Plate KH; Harter PN; Baumgarten P
J Mol Histol; 2021 Apr; 52(2):233-243. PubMed ID: 33528717
[TBL] [Abstract][Full Text] [Related]
7. Effect of dural detachment on long-term tumor control for meningiomas treated using Simpson grade IV resection.
Fukushima Y; Oya S; Nakatomi H; Shibahara J; Hanakita S; Tanaka S; Shin M; Kawai K; Fukayama M; Saito N
J Neurosurg; 2013 Dec; 119(6):1373-9. PubMed ID: 24053497
[TBL] [Abstract][Full Text] [Related]
8. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
[TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade.
Mahzouni P; Movahedipour M
Pathol Res Pract; 2012 Apr; 208(4):221-4. PubMed ID: 22420924
[TBL] [Abstract][Full Text] [Related]
10. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
13. World Health Organization Grade II Meningiomas: The Role of Adjuvant/Salvage Gamma Knife Surgery After Initial Surgery and Prognostic Factor Assessment.
Liu X; Shan B; Wang M; Xu J
World Neurosurg; 2018 Jan; 109():e352-e362. PubMed ID: 28987849
[TBL] [Abstract][Full Text] [Related]
14. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
15. Molecular biological determinations of meningioma progression and recurrence.
Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin expressions correlate with WHO grades and predict recurrence in meningiomas.
Arikök AT; Onder E; Seçkin H; Kaçar A; Fesli R; Oğuz AS; Alper M
Brain Tumor Pathol; 2014 Apr; 31(2):94-100. PubMed ID: 23793814
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations associated with progression and recurrence in meningiomas.
Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
[TBL] [Abstract][Full Text] [Related]
18. The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas.
Sughrue ME; Kane AJ; Shangari G; Rutkowski MJ; McDermott MW; Berger MS; Parsa AT
J Neurosurg; 2010 Nov; 113(5):1029-35. PubMed ID: 20380529
[TBL] [Abstract][Full Text] [Related]
19. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and prognostic factors of WHO II and III adult spinal meningiomas: analysis of 25 cases in a single center.
Ye J; Lv G; Qian J; Zhu J; Han R; Luo C
J Neurooncol; 2016 Jun; 128(2):349-56. PubMed ID: 27056111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
